Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Effects of Bosentan (Tracleer) in the Course of Pulmonary Artery Hypertension Induced by Hypoxia

This study has been completed.
Information provided by:
Assistance Publique - Hôpitaux de Paris Identifier:
First received: December 1, 2005
Last updated: October 16, 2008
Last verified: March 2007

Excessive rise in pulmonary artery pressure induced by low oxygen tension (hypoxia) is one of the factors implicated in high-altitude pulmonary oedema. Plasma ET1 increases in subjects exposed to high altitude and is correlated to pulmonary artery pressure.

The aim of the study is to investigate whether blockade of ET1 receptors would reduce the acute rise in systolic pulmonary artery pressure induced by hypoxia.

Condition Intervention Phase
Hypoxia-Induced Pulmonary Artery Hypertension
Drug: Bosentan
Drug: Bosentam TRACLEER
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Effects of Bosentan (Tracleer) in the Course of Pulmonary Artery Hypertension Induced by Hypoxia

Resource links provided by NLM:

Further study details as provided by Assistance Publique - Hôpitaux de Paris:

Primary Outcome Measures:
  • To investigate whether bosentan compared to placebo reduces hypoxia-induced increase in pulmonary artery pressure in healthy subjects and in subjects with past history of high-altitude pulmonary oedema [ Time Frame: during the study ]

Secondary Outcome Measures:
  • To compare [ Time Frame: during the study ]
  • pulmonary artery pressure response to exercise, [ Time Frame: during the study ]
  • exercise capacity, [ Time Frame: during the study ]
  • oxygen desaturation, [ Time Frame: during the study ]
  • and to assess the global safety [ Time Frame: during the study ]

Enrollment: 20
Study Start Date: January 2006
Study Completion Date: April 2008
Primary Completion Date: April 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Experimental and Placebo Comparator administered in random order during to successive experimental phase
Drug: Bosentan
Single dose administration of 250 mg bosentan (2 pills Tracleer 125 mg) or placebo
Other Name: TRACLEER
Placebo Comparator: 2
Experimental and Placebo Comparator administered in random order during to successive experimental phase
Drug: Bosentam TRACLEER
Single dose administration of 250 mg bosentan (2 pills Tracleer 125 mg) or placebo

Detailed Description:
Patients will be examined on a variable load supine bicycle ergometer. The exercise table will be tilted laterally by 20 to 30 degrees to the left. PASP will be assessed using Doppler echocardiography at rest and during during supine bicycle exercise in NORMOXIA and hypoxia. Exposure to normobaric hypoxia will be performed by breathing a hypoxic gas mixture at sea level during 90 minutes (12,3 % O2 + 87.7 % N2) reproducing conditions at 4300 m altitude. Exercise will be started at an initial workload of 40 watts and increased by 10 watts every minute to reach a workload level defined by a heart rate (HR) corresponding to 50% of the estimated maximal aerobic power

Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • 20 non smoker healthy volunteers : 10 resistant to high-altitude pulmonary oedema and 10 susceptible subjects, without history of cardiac or pulmonary disease or asthma, after a complete clinical examination and safety laboratory measurements prior to randomization, and after giving informed written consent.

Exclusion Criteria:

  • antecedent of lung disease notably with asthmatic antecedent or HTAP
  • antecedent of heart disease
  • female genital organ
  • systolic blood pressure < 85 mmHg or > 160 mmHg after 5 minutes of lengthened rest.
  • sentimentality in a medicine, in particular in a bosentan or in one of the excipients of the tablet.
  • hepatic incapacity moderated to severe correspondent in the class B or C of the classification of Child-Pugh (cf Pharmacokinetics) Rate serous hepatic aminotransferases, aspartate aminotransferases( ASAT) and\or alanine aminotransférases ( ALAT), superior to 3 times the superior limit of the normal before the started of the treatment.
  • pointed or chronic systematic diseases.
  • presence of antibody anti-HIV, of anti-HVC antibody, antigens Hbs and\or antibody anti-Hbc. - active addiction to smoking.
  • alcohol abuse and of toxins.
  • Taking of concomitant medicines except those allowed the chapter concomitant treatments.
  • signs, symptoms or values of the biological examinations situated except the clinically acceptable values for healthy subjects with or without antecedent of OPHA.
  • common(current) ingestion of excessive quantities of tea, coffee(cafe), chocolate and\or drinks containing some caffeine (> 5 cups / day, is approximately 500 mg of caffeine a day).
  • consumption of juice of grapefruit and\or herb tea on base of St.
  • John's wort
  • Don of blood in 3 months preceding the study.
  • Persons in period of exclusion on the national file of the persons lending itself to the biomedical search(research) without direct individual profit.
  • refusal or linguistic or psychic incapacity to sign the lit(enlightened) assent.
  • subject which can not submit itself to the constraints of the protocol (for example, not cooperative, incapable to go(surrender) to the visits of follow-up and probably incapable to finish the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00260819

Centre d'Investigation Clinique 9201 Hôpital Européen Georges Pompidou
Paris, France, 75908 cedex 15
Sponsors and Collaborators
Assistance Publique - Hôpitaux de Paris
Principal Investigator: Michel AZIZI, MD,PhD Assistance Publique - Hôpitaux de Paris
  More Information

Responsible Party: Isabelle Brindel, Department Clinical Research of Developpement Identifier: NCT00260819     History of Changes
Other Study ID Numbers: P050502
Study First Received: December 1, 2005
Last Updated: October 16, 2008

Keywords provided by Assistance Publique - Hôpitaux de Paris:
Hypoxia-induced pulmonary artery hypertension
High-altitude pulmonary oedema
ETA receptor antagonist

Additional relevant MeSH terms:
Hypertension, Pulmonary
Vascular Diseases
Cardiovascular Diseases
Signs and Symptoms, Respiratory
Signs and Symptoms
Lung Diseases
Respiratory Tract Diseases
Antihypertensive Agents
Endothelin Receptor Antagonists
Molecular Mechanisms of Pharmacological Action processed this record on May 25, 2017